Navigation Links
Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
Date:11/25/2008

SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Piper Jaffray 20th Annual Health Care Conference on December 3, 2008 at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time) at the New York Palace Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

     Contacts: Jack Lief                             Mary Claire Duch
               President and CEO                     WeissComm Partners
                                                     Media Relations
               David Walsey                          212.301.7228
               Director, Corporate Communications

               Arena Pharmaceuticals, Inc.
               858.453.7200, ext. 1682

    http://www.arenapharm.com

'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
2. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
3. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
4. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
5. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
10. Arena Pharmaceuticals Announces Public Offering of Common Stock
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... Standard ... 75, an annual ranking and recognition of the largest closely held companies headquartered ... ranked from 2008-2016. In addition, Standard Process was awarded the Talent Award for ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new residential mental health treatment program in Chino ... issues such as severe anxiety, depression, bi-polar disorder, and other related issues. , ...
(Date:11/30/2016)... ... 30, 2016 , ... The Cronovo Smartwatch, the first on ... consumers at an affordable price, is now available on the crowdfunding website ... game changer” when it comes to the smartwatch. , "With Cronovo, we’ve combined ...
(Date:11/30/2016)... ... 2016 , ... The Valley’s leading orthopedic practice, OrthoArizona - ... North Phoenix and Chandler locations. , The new North Phoenix location is located ... 3rd St, Suite 300 in Phoenix. The practice’s new Chandler location is conveniently ...
(Date:11/30/2016)... ... November 30, 2016 , ... BrightStar Care of Wellington , a ... was recently named the 2016 Provider and Employer of Choice by Home Care Pulse. ... scores, and only providers with the highest quality receive the Best of Home Care ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 According to a ... by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical ... Nephrology, Infectious Diseases) - Forecast to 2021" published ... USD 60.22 Billion in 2016. This market is ... during the forecast period (2016-2021) to reach USD ...
(Date:12/2/2016)... In the first ever attempt to include ... from C. sativa, the Hebrew University in Jerusalem, the ... II , the Universita` del Piemonte Orientale and Phytoplant ... and unified inventory of phytocannabinoids of different botanical origin. ... remarkable chemical and structural diversity of phytocannabinoids. As a ...
(Date:12/2/2016)... , Dec. 2, 2016  Eli Lilly and ... financial guidance for 2017 and provide updated financial guidance ... also conduct a conference call on that day with ... company,s financial guidance. The conference call will ... general public can access a live webcast of the ...
Breaking Medicine Technology: